造血
体细胞
血液学
祖细胞
免疫学
生物
血细胞
干细胞
遗传学
基因
作者
Lachelle D. Weeks,Benjamin L. Ebert
出处
期刊:Blood
[American Society of Hematology]
日期:2023-11-06
卷期号:142 (26): 2235-2246
被引量:19
标识
DOI:10.1182/blood.2023022222
摘要
Abstract Clonal hematopoiesis (CH) is described as the outsized contribution of expanded clones of hematopoietic stem and progenitor cells (HSPCs) to blood cell production. The prevalence of CH increases dramatically with age. CH can be caused by somatic mutations in individual genes or by gains and/or losses of larger chromosomal segments. CH is a premalignant state; the somatic mutations detected in CH are the initiating mutations for hematologic malignancies, and CH is a strong predictor of the development of blood cancers. Moreover, CH is associated with nonmalignant disorders and increased overall mortality. The somatic mutations that drive clonal expansion of HSPCs can alter the function of terminally differentiated blood cells, including the release of elevated levels of inflammatory cytokines. These cytokines may then contribute to a broad range of inflammatory disorders that increase in prevalence with age. Specific somatic mutations in the peripheral blood in coordination with blood count parameters can powerfully predict the development of hematologic malignancies and overall mortality in CH. In this review, we summarize the current understanding of CH nosology and origins. We provide an overview of available tools for risk stratification and discuss management strategies for patients with CH presenting to hematology clinics.
科研通智能强力驱动
Strongly Powered by AbleSci AI